Furthermore, we identified a strong reduction of paxillin phosphorylation in cancer cells of recipients treated with 6B345TTQ (4.72% of total area) compared with control mice treated with DMSO (9.79% of total area) (Figure 6, H and J). The gene discussed is PXN; the disease is cancer.